RxDoctor Payments Data

Bridget Shepherd Depaul, APRN

Family · Lexington, KYNPI 1750751517

Payments from drug & device makers

$10,063in general payments, 2019–2025

Across 664 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$677
  • Pfizer$628
  • GSK$627
  • Otsuka America Pharmaceutical, Inc.$350
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$9,96399%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,063 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$40,267
Medicare patients
106
Services billed
655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$83,597
JardianceEmpagliflozin60$57,917
VraylarCariprazine Hcl31$45,770
CreonLipase/Protease/Amylase15$45,219
EliquisApixaban23$31,759
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$25,926
JanuviaSitagliptin Phosphate29$23,780
XareltoRivaroxaban18$16,585
LinzessLinaclotide12$12,664
Tresiba Flextouch U-200Insulin Degludec11$10,287
FarxigaDapagliflozin Propanediol17$9,688
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$8,404
VascepaIcosapent Ethyl14$6,236
Breo ElliptaFluticasone/Vilanterol12$5,605
MyrbetriqMirabegron11$5,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Creon, Linzess, Synthroid$2,036$104,62589 claims
Novo NordiskOzempic$1,417$83,59775 claims
Boehringer IngelheimJardiance$337$57,91760 claims
PfizerEliquis$628$31,75923 claims
GSKTrelegy Ellipta, Breo Ellipta$627$31,53143 claims
MerckJanuvia$64$23,78029 claims
Johnson & JohnsonXarelto$28$16,58518 claims
AstraZenecaFarxiga$311$9,68817 claims
Astellas Pharma US IncMyrbetriq$317$5,56511 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$1,644150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →